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Abstract
Objectives—We estimated HIV prevalence and risk factors among persons receiving mental 
health treatment in Philadelphia, Pennsylvania, and Baltimore, Maryland, January 2009 to August 
2011.
Methods—We used a multisite, cross-sectional design stratified by clinical setting. We tested 
1061 individuals for HIV in university-based inpatient psychiatric units (n = 287), intensive case-
management programs (n = 273), and community mental health centers (n = 501).
Results—Fifty-one individuals (4.8%) were HIV-infected. Confirmed positive HIV tests were 
5.9% (95% confidence interval [CI] = 3.7%, 9.4%) for inpatient units, 5.1% (95% CI = 3.1%, 
8.5%) for intensive case-management programs, and 4.0% (95% CI = 2.6%, 6.1%) for community 
mental health centers. Characteristics associated with HIV included Black race, homosexual or 
bisexual identity, and HCV infection.
Conclusions—HIV prevalence for individuals receiving mental health services was more than 4 
times as high as in the general population. We found a positive association between psychiatric 
symptom severity and HIV infection, indicating that engaging persons with mental illness in 
appropriate mental health treatment may be important to HIV prevention. These findings reinforce 
recommendations for routine HIV testing in all clinical settings to ensure that HIV-infected 
persons receiving mental health services are identified and referred to timely infectious disease 
care.
People with serious mental illness (SMI) are at increased risk for being infected with HIV. 
Risk factors associated with HIV infection among persons with SMI mirror those in the 
general population and include unprotected sexual activity and injection drug use (IDU).1–5 
Studies that estimated HIV prevalence from samples of patients with SMI during the 1990s 
and early 2000s found that HIV prevalence ranged from 1% to 23%.6–16 The wide variation 
in estimates has been attributed to small sample sizes, the use of regional convenience 
samples, differences in sampling frames, and inadequate adjustment for confounding effects 
of factors associated with HIV risk.17,18
Analysis of administrative data indicates that many HIV-infected persons who receive 
Medicaid also have comorbid mental illnesses. Walkup et al. found that among persons in 
the New Jersey HIV/AIDS registry receiving Medicaid, 5.7% had a diagnosis of 
schizophrenia,19 much higher than the prevalence of schizophrenia in the general 
population, which is estimated to be about 1%.20 A clear weakness of this method is that 
HIV diagnoses identified in administrative records may not capture all HIV diagnoses and 
may not be linked to confirmed HIV-positive test results. An approach to measuring rates of 
HIV among individuals with SMI taken by investigators in Philadelphia, Pennsylvania, was 
to conduct HIV testing on remnant blood specimens collected from patients on 2 inpatient 
psychiatric units in the city. In this study, 10.1% of patients were found to be HIV-infected. 
Chart reviews up to the time of testing of the remnant blood failed to find documentation of 
previous HIV diagnosis in the clinical record for approximately one third of these persons. 
However, this study used a very specific sample that does not generalize to all patients 
seeking mental health services.16
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As the demographics of the HIV epidemic have shifted in the past decade, the degree to 
which HIV prevalence among persons with SMI has changed remains unclear. Accurate 
estimates of HIV prevalence among these persons and more information about access to and 
retention in care for HIV-positive persons with SMI is needed.
The approval of rapid HIV testing by the US Food and Drug Administration and widespread 
availability of multiple rapid testing assays provides new opportunities for HIV testing and 
more efficient determination of prevalence estimates in hard-to-reach populations. Rapid 
HIV testing results can be obtained in approximately 20 minutes, allowing delivery of 
immediate posttest counseling and referral and linkage to HIV care. Prevention services for 
persons with preliminary positive test results can also reduce risks of transmission to others. 
The rapid turnaround for obtaining and delivering test results increases the flexibility of 
service delivery and might be useful for testing those with SMI within mental health 
settings. This is particularly important as the mental health system has been increasingly 
called upon to provide basic medical and preventive health services21–24 for those with SMI 
and is the most common place for where they receive care.25 Rapid testing thus holds great 
promise for integrating routine HIV testing into ongoing mental health services in a variety 
of clinical settings. The specificity of current US Food and Drug Administration–approved 
rapid HIV tests is high.26 Sensitivity for established infections is also high, but currently 
available rapid tests do not detect early infections that can be detected by laboratory tests.27
Prevention services for HIV-positive patients in mental health centers have the potential to 
reduce risks of transmission to others. This is consistent with a positive prevention model 
proposed by Sikkema et al.28 although the empirical evidence to date has been mixed,29–31 
with additional studies in progress.32 There is also an opportunity for rapid testing to 
facilitate linkage to infectious disease care for these individuals.33–36
The purpose of this study was to use rapid HIV testing to estimate HIV prevalence and 
examine risk factors associated with HIV infection among people receiving treatment in the 
mental health system. We focused on 2 large urban communities (Philadelphia, PA, and 
Baltimore, MD) that have a high burden of HIV infection. By drawing the study sample 
from inpatient psychiatric units, outpatient community mental health centers (CMHCs), and 
outpatient intensive case management (ICM) programs, we captured patients served by the 3 
predominant modalities of mental health service delivery in the United States.
METHODS
We used a multisite, cross-sectional design stratified across 3 clinical settings (inpatient 
psychiatric units, CMHCs, and ICM programs) with convenience sampling. We selected 
Philadelphia and Baltimore because both cities are among the major metropolitan areas in 
the United States with the highest HIV prevalence.37 In Baltimore, participants were 
recruited from 1 inpatient unit, 2 ICMs, and 1 CMHC. In Philadelphia, participants were 
recruited from 2 inpatient units, 2 ICMs, and 2 CMHCs. For the inpatient units, participants 
were recruited from the roster of admissions. Interview staff approached persons based on 
the length of time they had been on the unit, starting with those had been admitted the 
longest because they were more likely to be stabilized and able to participate in the study. 
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For the CMHCs and ICM programs, participants were approached after they had checked in 
for their appointment at the facility. In each setting, providers were given the opportunity to 
recommend exclusion of anyone who they felt was clinically compromised and too unstable 
to participate. For all settings, persons were eligible to participate if they were aged 18 years 
or older, understood spoken English, were willing to provide contact information, were 
competent to consent to the study procedures (demonstrated through a verbal quiz of the 
content of the consent form), and agreed to a confidential rapid HIV test.
After providing informed consent, the participants received a rapid HIV test in accordance 
with Centers for Disease Control and Prevention and local testing guidelines. Trained 
interviewers then administered a 45- to 60-minute face-to-face interview. The responses to 
the interview were recorded on paper and later transferred to a computer database. 
Immediately following the interview, the HIV test results were delivered to participants. 
Results were provided after participants completed the interview to prevent influencing 
responses. For those who tested preliminary positive, a second oral swab was collected for 
confirmatory testing with Western blot, which was sent to a commercial laboratory (Quest 
Diagnostics). All persons identified as HIV-infected were reported to their respective city 
health departments regardless of whether they had indicated a previous HIV diagnosis. The 
city health departments confirmed whether reports of HIV infections were known previously 
or if they were new reports. Participants were compensated $20 for their time taking the 
survey and HIV test.
Persons enrolled in other research trials were allowed to participate. Known HIV-infected 
individuals were eligible to participate to avoid underestimating prevalence. To perform 
point-of-care HIV testing outside a standard clinical laboratory, Clinical Laboratory 
Improvement Amendment waivers were obtained for all the study sites.
In addition to the interviews and HIV testing, we conducted chart abstractions for all 
participants to collect information regarding psychiatric diagnoses.
Measures
A face-to-face structured interview was used to collect information on participant 
demographics, past-6-month drug and alcohol use, sexual practices, hepatitis and sexually 
transmitted infections (STIs), concerns about HIV, and HIV testing history. A copy of the 
interview was provided to participants so they could read along if they were able to do so, 
but the procedures did not assume any functional level of literacy. We used the Short Form 
12-Item Health Survey (SF-12) from the Medical Outcomes Study to assess comprehensive 
health status and functioning.38 We used the Risk Assessment Battery (RAB) Prescreen 
Questionnaire39,40 to assess sexual orientation, homelessness and unstable housing, 
involvement with the criminal justice system, type and frequency of drug use, and, for IDU, 
source of needles used during the past 6 months. We assessed psychiatric symptoms with the 
24-item Behavior and Symptom Identification Scale (BASIS-24).41 We included 6 subscales 
of the BASIS-24 in analyses: depression/functioning, relationships, self-harm, emotional 
lability, psychosis, and substance abuse. The BASIS-24 is well suited for this study because 
it is not diagnosis-specific; rather, it measures a broad range of symptoms of mental illness 
across a broad range of diagnoses. We generated diagnostic codes on the basis of chart 
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abstraction. As psychiatric and substance abuse disorders commonly co-occur, we created 
the following algorithm to create 3 mutually exclusive categories based on Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition,42 diagnoses: (1) those with a 
psychiatric diagnosis only, (2) those who had co-occurring psychiatric and substance 
dependence or abuse diagnoses, and (3) those who had a substance dependence or abuse 
diagnosis only.
Analyses
We performed univariable analyses of demographic characteristics and risk factors 
associated with HIV prevalence by using Poisson regression with a robust standard error 
with generalized estimating equation procedures.43 We estimated P values by using the type 
III likelihood ratio χ2 test to test for overall differences in HIV prevalence among the levels 
of a characteristic.
We estimated the association between continuous variables (RAB score, SF-12, and 
BASIS-24 scores) and HIV status by using univariable Poisson models and present the 
prevalence ratios in terms of a 1-unit increase for these continuous variables. Because the 
RAB drug risk score was highly skewed, it was utilized as a dichotomous variable (0, 1) for 
this study.
We used a multivariable Poisson model to estimate adjusted prevalence ratios with the 
following guidelines. First, we included a priori variables in the multivariable model 
regardless of the univariable Poisson model prevalence results. The a priori variables were 
site, age, gender, race, and sexual identity. We chose these because they were likely to be 
risk factors (age, gender, race, and sexual orientation) or a blocking factor (site) and we 
wanted to control for these variables regardless of statistical significance. Next, we included 
all other factors listed in Tables 1 and 2 in the multivariable model if the univariable model 
P value was .1 or less. We estimated the HIV unadjusted prevalence and 95% confidence 
interval (CI) for all levels of the categorical demographic characteristics and risk factors by 
using the univariable Poisson models (Table 1). We present the unadjusted and adjusted 
prevalence ratios with 95% CI and P values for the final models. For all analyses, we 
considered a P value of .05 or less statistically significant.
RESULTS
The study sample of 1061 persons included 621 men (58.8%) and 436 women (41.2%) with 
4 declining to specify gender (0.4%); most participants were Black (65.7%). Overall, 51 
(4.8%; 95% CI = 3.7%, 6.3%) had confirmed positive HIV test results. Among the 570 
people who only had a psychiatric disorder, 332 (58.3%) had schizophrenia or another 
psychotic disorder, 227 (39.8%) has an affective disorder, and 11 (1.9%) had another 
psychiatric diagnosis. Among the 350 with a psychiatric disorder as well as a co-occurring 
substance abuse disorder, 141 (40.3%) had schizophrenia or another psychotic disorder, 208 
(59.4%) had an affective disorder, and 1 (0.3%) had another psychiatric diagnosis. There 
were 141 people with only a substance abuse disorder and no other psychiatric diagnoses. 
The rate of infection was higher in Baltimore (5.9%; 95% CI = 4.1%, 8.6%) than in 
Philadelphia (3.9%; 95% CI = 2.7%, 5.8%), but this difference was not statistically 
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significant. We tested 288 participants from university-based inpatient psychiatric units, of 
whom 17 (5.9%; 95% CI = 3.7%, 9.4%) were HIV-infected; 273 participants from ICM 
programs, of whom 14 (5.1%; 95% CI = 3.1%, 8.5%) were HIV-infected; and 501 
participants from CMHCs, of whom 20 (4.0%; 95% CI = 2.6%, 6.1%) were HIV-infected; 
these differences were not statistically significant (P = .47; Table 1).
The majority (76.0%; 95% CI = 64.6%, 88.3%) of persons who tested positive were already 
aware of their HIV status. In Philadelphia, a total of 608 participants were tested, of whom 
24 (3.9%; 95% CI = 2.7%, 5.8%) tested positive. Of the 24 participants testing positive, 21 
(87.5%; 95% CI = 74.7%, 99.0%) reported that they had previously known that they were 
HIV-infected. In Baltimore, a total of 454 participants were tested, of whom 27 (5.9%; 95% 
CI = 4.1%, 8.6%) tested positive. Seventeen (65.4%; 95% CI = 48.1%, 84.7%) participants 
with positive test results reported that they had previously known that they were HIV-
infected.
Age was significantly associated with HIV status (P = .04); those who were aged 40 to 49 
years had the highest HIV prevalence (6.7%; 95% CI = 4.5%, 9.9%), followed by those who 
were aged 50 years or older (5.7%; 95% CI = 3.8%, 8.5%). We also found race to be 
significantly associated with HIV status (P = .02), with Black participants having the highest 
HIV prevalence (6.2%; 95% CI = 4.7%, 8.3%). Participants who reported current 
homelessness had a higher prevalence of HIV compared with those who were not currently 
homeless (8.1%; 95% CI = 4.9%, 13.3% vs 4.2%; 95% CI = 3.1%, 5.8%; P = .03). HIV 
prevalence was significantly higher among participants who reported being coinfected with 
HCV (10.8%; 95% CI = 6.9%, 17.0% vs 3.7%; 95% CI = 2.7%, 5.2%; P < .001) and among 
those who identified as homosexual or bisexual compared with those who identified as 
heterosexual (10.4%; 95% CI = 5.8%, 18.7% vs 4.2%; 95% CI = 3.1%, 5.7%; P = .01). We 
found no significant differences in rates of HIV prevalence by level of care, study site, 
gender, marital or cohabitation status, income, education, having had an STI in the past 12 
months, non-injection drug use in the past 4 weeks, or psychiatric diagnosis (Table 1).
Table 2 examines differences between participants on the RAB, SF-12, and BASIS-24 by 
HIV status to examine associations between HIV infection and drug and sexual risk, social 
and emotional well-being, and severity of symptoms of mental illness. There were no 
differences between those who tested positive or negative for HIV on any of the indicators 
of health-related quality of life as measured by the SF-12. We found significant differences 
for emotional lability (P = .046) and for the total RAB score (P=.045). Although we found 
no statistical significance for the BASIS-24 overall score (P = .06) the P value suggests 
relevance of the difference in the scores.
Table 3 presents the multivariable analyses. Participants were more likely to be HIV-
infected if they were Black (adjusted prevalence ratio [aPR] = 5.71; 95% CI = 1.58, 20.67) 
compared with White (P = .01); homosexual or bisexual (aPR = 2.27; 95% CI = 1.03, 5.00) 
compared with heterosexual (P = .04); ever been told that they had HCV infection (aPR = 
2.28; 95% CI = 1.23, 4.22; P = .01); and had a higher BASIS-24 score (aPR = 1.69; 95% CI 
= 1.01, 2.83; P = .049).
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DISCUSSION
This study is one of the largest to date to estimate HIV prevalence and risk factors among 
persons receiving treatment in mental health settings. By recruiting participants from 3 
distinct settings (inpatients, outpatients receiving routine care, and outpatients receiving 
intensive case management services), we evaluated patients served by the 3 predominant 
modes of delivering mental health services in the United States.44 Consistent with previous 
studies, we found that HIV infection is highly prevalent among persons receiving mental 
health care. A total of 4.8% (3.7%–6.3%) of participants in our study were HIV-infected, 
which is more than 4 times the overall prevalence in Philadelphia (1.4%) and Baltimore 
(1.3%).45,46 We also found that characteristics associated with HIV status followed a pattern 
similar to the general population and included Black race, homosexual or bisexual identity, 
and HCV infection. The association between HIV status and HCV infection is likely a 
marker of lifetime IDU among this population; however, participants were only asked about 
IDU in the past 6 months.
The results of the current study also showed that persons with more severe symptoms of 
mental illness were at higher risk for being HIV-infected. This is consistent with a recent 
study that examined the association of HIV risk and psychiatric symptom severity by using 
the Colorado Symptom Index and found a 47% increased risk for HIV among persons with 
scores of 30 or greater (a criterion score for severe psychiatric symptoms) compared with 
those with scores lower than 30.47 Although psychiatric severity appeared to be associated 
with HIV infection, we did not find any differences in HIV prevalence when stratified by 
service setting, indicating that persons receiving care in more acute treatment settings (e.g., 
inpatient units) were not more likely to be HIV-infected. Our findings suggest that specific 
neurocognitive or psychiatric symptoms may be associated with HIV prevalence 
independent of treatment needs at the time of testing.48–50
Although our study found a high prevalence of HIV among those receiving mental health 
care, we detected relatively few new HIV cases. However, these new cases of HIV represent 
an important failure in the public health and mental health system of care. Higher rates of 
undetected HIV have been found in other groups in the community, but our sample is 
gleaned from individuals who are actively receiving mental health care in a hospital or 
community-based clinic. Both the Centers for Disease Control and Prevention and the 
Institute of Medicine recommend HIV screening in all clinical settings, including mental 
health settings, to increase identification of those infected and strengthen access to care.51 
However, since these recommendations were released, little progress has been made toward 
integrating HIV testing into mental health care visits.52–56 Overcoming system-level 
barriers, including identifying sources of funding for training, credentialing, and 
procurement of point-of-care rapid HIV testing kits needed for on-site HIV testing, may be 
required to ensure wider adoption of HIV testing in mental health care settings.
As with HIV screening conducted in any setting, ensuring that those who are identified with 
HIV are linked to, retained in, and adhere to HIV care is vitally important. Ensuring linkage 
for HIV-infected persons with mental illness to HIV care in the community can be very 
difficult because of issues such as ongoing substance abuse, unstable housing, and lack of 
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employment. However, the opportunity to initiate referrals in specialty mental health 
settings is enhanced by long-term caring relationships that are developed with many persons 
with SMI. Both HIV and mental illness are chronic conditions with significant health 
burdens and associated economic costs57 that have traditionally been treated with 
fragmented rather than integrated approaches. There have been several calls for the 
integration of public health and mental health systems58–60 and a greater understanding of 
the health disparities among individuals with mental illnesses.61–63 To address these 
concerns, the National AIDS Strategy suggests a wide range of approaches including policy 
integration of mental health promotion, prevention of mental illness, and the control and 
prevention of other chronic diseases.49 Better integration of HIV testing in these settings 
will enhance the identification of HIV infection among persons with mental illnesses and 
improve linkage to and, presumably, retention in HIV medical care. Indeed, public health 
systems in the future should focus on developing tailored treatments for complex co-
occurring conditions.50 This is particularly relevant because mental health treatment may 
prevent HIV acquisition and transmission in a similar way as substance abuse treatment 
prevents HIV acquisition and transmission.48–50
These findings also support treatment as prevention among people with mental illnesses who 
know they are HIV-infected. We need to continue to expand risk reduction and other 
prevention services for persons with co-occurring mental illnesses and HIV within existing 
mental health service settings. These data suggest the need for risk reduction counseling 
within these settings; such counseling could be of great public health significance.
This study is subject to several limitations. First, the data were cross-sectional so we cannot 
make any causal inferences between SMI and HIV infection. Second, although efforts were 
made to recruit patients systematically, only a small number of mental health care venues in 
Philadelphia and Baltimore were included and study participants were not recruited 
randomly within these venues. Therefore, the findings from this study may not be 
representative of persons with SMI in these venues or in the 2 cities. Third, some individuals 
were ineligible to participate because of the severity of symptoms of their mental illnesses 
and lack of competence to provide informed consent based on a 2-step competence 
determination procedure. However, the exclusion of these individuals likely biased our 
findings toward the null because we found that more severe mental illness was associated 
with a higher rate of HIV infection. Finally, we were not able to determine immunological 
status, viral loads, and treatment status of the HIV-infected persons included in these 
analyses. Additional research should determine the extent to which persons with mental 
illness are receiving HIV care and treatment and collect data on immunologic and viral load 
status of patients with SMI. Determination of in-care viral load for persons with mental 
illnesses may provide insights about disparities in access to, use of, and compliance with 
HIV medical care and suggest possible interventions to address these.64
The results of this investigation provide some clues as to fruitful directions of future 
research in HIV among persons with mental illnesses. It would be useful to examine if 
different risk groups are more likely to miss detection in mental health settings. Community 
mental health services should routinely include programs that explore sexuality and positive 
adjustment among consumers of all sexual orientations and to provide information and 
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referral to other community services. If mental health centers are to serve as “medical 
homes” for persons with mental illnesses,65 they need to embrace the need to provide 
comprehensive screening and referral for HIV and other STIs.
In conclusion, we found high rates of HIV infection among persons receiving mental health 
services in Philadelphia and Baltimore, which is consistent with findings from previously 
published reports. We also found a positive association between the severity of psychiatric 
symptoms and HIV infection, which indicates that engaging persons with mental illness in 
appropriate mental health treatment may be an important approach to HIV prevention. 
Receipt of appropriate mental health care may be a particularly effective approach to HIV 
prevention and care. As progress is made in integrating mental health care and HIV 
prevention programs, this could promote increased detection of HIV, enhanced linkage to 
and retention in HIV care, and improved adherence to psychotropic and antiretroviral 
medications. In this way, integrated HIV testing and integrated delivery of health services 
could help reduce the spread of HIV and improve the health and well-being of persons who 
are already HIV-infected.
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TABLE 2
Substance Use and Risk Behaviors, Health Status, and Psychiatric Symptoms by HIV Status Among Persons 
Receiving Treatment in Mental Health Settings: Philadelphia, PA, and Baltimore, MD, January 2009–August 
2011
Variable
HIV Status, No. (%) or Mean ±SD
PR (95% CI) PaHIV-Infected (n = 51) Non–HIV-Infected (n = 1010)
RAB40
 Drug risk score 0 47 (92.2) 978 ±96.8 4.6 (3.5, 6.1) .07
 Drug risk score 1 4 (7.8) 32 ±3.2 11.1 (4.4, 28.0)
 Sexual risk score, range 0–18 3.1 ±2.6 2.8 ±2.1 1.06 (0.93, 1.20) .39
 Overall score, range 0–19 3.9 ±4.4 3.0 ±2.8 1.07 (1.00, 1.14) .045
SF-1238
 Physical functioning score 42.7 ±12.3 44.5 ±11.4 1.01 (0.99, 1.04) .24
 Role limitation physical score 44.9 ±10.0 42.0 ±13.4 1.02 (0.99, 1.04) .24
 Pain score 42.7 ±13.3 42.1 ±13.4 1.00 (0.98, 1.02) .74
 General health score 38.5 ±11.3 40.3 ±11.8 0.99 (0.97, 1.01) .29
 Vitality score 49.1 ±12.4 48.9 ±11.7 1.00 (0.98, 1.03) .88
 Social functioning score 38.2 ±15.5 40.5 ±13.9 0.99 (0.97, 1.01) .27
 Role limitation emotional score 36.6 ±13.2 37.9 ±12.7 0.99 (0.97, 1.01) .47
 Mental health score 42.5 ±13.8 42.7 ±12.5 1.00 (0.98, 1.02) .96
 Aggregate physical health score 44.4 ±10.1 44.3 ±10.3 1.00 (0.98, 1.03) .93
 Aggregate mental health score 40.5 (14.1) 41.4 ±12.2 0.99 (0.97, 1.02) .66
BASIS-2441
 Depression functioning 1.8 ±0.8 1.6 ±0.9 1.22 (0.95, 1.59) .12
 Interpersonal relationships 2.4 ±1.0 2.6 ±0.9 0.83 (0.62, 1.11) .21
 Self-harm 0.5 ±0.9 0.3 ±0.8 1.21 (0.93, 1.58) .16
 Emotional lability 2.0 ±1.2 1.6 ±1.1 1.29 (1.01, 1.65) .045
 Psychosis 1.3 ±1.2 1.1 ±1.1 1.19 (0.93, 1.52) .17
 Substance abuse 1.0 ±1.1 0.8 ±1.0 1.19 (0.93, 1.55) .16
 Overall score 1.7 ±0.6 1.5 ±0.6 1.52 (0.98, 2.36) .06
Note. BASIS-24 = The Behavior and Symptom Identification Scale; CI = confidence interval; PR = prevalence ratio; RAB = Risk Assessment 
Battery; SF-12 = Short-Form 12-Item Health Survey. Numbers might not add to total because of missing data.
a
P value from Wald statistic for type 3 generalized estimating equation analysis.
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TABLE 3
Final Model, Unadjusted and Adjusted Association Between Select Participant Characteristics and HIV Status 
Among Persons Receiving Treatment in Mental Health Settings: Philadelphia, PA, and Baltimore, MD, 
January 2009–August 2011
Variable PR (95% CI) P APRa (95% CI) P
Study site
 Philadelphia (Ref) 1.00 1.00
 Baltimore 1.51 (0.88, 2.58) .13 1.56 (0.91, 2.66) .11
Age, y
 18–29 (Ref) 1.00 1.00
 30–39 0.49 (0.08, 2.89) .43 0.45 (0.08, 2.65) .38
 40–49 2.96 (0.91, 9.71) .07 2.24 (0.65, 7.66) .2
 ≥ 50 2.53 (0.77, 8.29) .13 2.11 (0.60, 7.37) .24
Gender
 Female (Ref) 1.00 1.00
 Male 0.85 (0.50, 1.46) .57 1.12 (0.60, 2.07) .73
Race
 White (Ref) 1.00 1.00
 Black 6.09 (1.49, 24.91) .01 5.79 (1.60, 20.90) .01
 Otherb 3.54 (0.72, 17.32) .12 3.80 (0.79, 18.37) .1
Sexual identity
 Heterosexual (Ref) 1.00 1.00
 Homosexual or bisexual 2.46 (1.27, 4.76) .01 2.21 (1.00, 5.00)
.049c
Housing status
 Currently homeless 1.92 (1.06, 3.48) .03 1.50 (0.79, 2.84) .22
 Not currently homeless (Ref) 1.00 1.00
STI, past 12 mo
 No (Ref) 1.00 1.00
 Yes 0.34 (0.05, 2.45) .29 0.34 (0.04, 2.58) .3
Any substance abuse disorder diagnosisd
 No (Ref) 1.00 1.00
 Yes 1.72 (1.00, 2.97) .05 1.25 (0.70, 2.22) .46
Ever told had hepatitis Ce
 No (Ref) 1.00 1.00
 Yes 2.92 (1.67, 5.12) < .001 2.24 (1.21, 4.16) .01
RAB40 overall score 1.07 (1.00, 1.14) .05 1.07 (0.97, 1.18) .16
BASIS-2441 overall score 1.52 (0.98, 2.35) .06 1.70 (1.02, 2.84) .041
APR = adjusted prevalence ratio; BASIS-24 = The Behavior and Symptom Identification Scale; CI = confidence interval; GED = general education 
development; HS = high school; PR = prevalence ratio; RAB = Risk Assessment Battery; STI = sexually transmitted infection.
aAdjusted for all variables in table.
b
Includes persons who indicated Asian, Hawaiian/Pacific Islander, American Indian/Alaska Native, and multiple races.
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c
This value was truncated to .049 from .0496 rather than rounded to .05 in order to make clear that it was statistically significant at the standard 
level of alpha.
d
Diagnostic codes were generated on the basis of chart abstraction. As psychiatric and substance abuse disorders commonly co-occur, we created 
the following algorithm to create 3 mutually exclusive categories based on Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition,42 diagnoses: (1) those with a psychiatric diagnosis only, (2) those who had co-occurring psychiatric and substance dependence or abuse 
diagnoses, and (3) those who had a substance dependence or abuse diagnosis only.
e
By a doctor, nurse, or other health care provider.
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